New Era of Preventing End-Stage Kidney Disease Act
Sponsored By: Representative Bilirakis
Introduced
Summary
Preventing end-stage kidney disease by creating NIDDK Centers of Excellence that fund research, expand provider and public education, and reach rural and underserved communities to better diagnose and treat rare kidney diseases.
Show full summary
- Researchers and clinicians: Establishes NIDDK Centers of Excellence on Rare Kidney Disease Research and funds grants and cooperative agreements to study causes, symptoms, diagnosis, progression, and treatments, including genotype‑phenotype relationships. It bars use of QALYs, DALYs, or similar measures that discriminate against people with disabilities in value assessments.
- Patients and families: Permits centers to cover patient care costs needed for research and to provide education on diagnosis, routine urinalysis, genetic testing, renal diet, and mental and emotional health resources. The bill emphasizes outreach and information programs for rural and underserved communities and people diagnosed with rare kidney diseases.
- Health systems and federal coordination: Supports clinical training, continuing education, and demonstration projects for diagnostic, prevention, control, and treatment methods and requires coordination with other NIH institutes and the FDA. Each center may receive up to 5 years of support with possible 5‑year extensions under peer review, and the bill authorizes $6 million per year for FY2026–2030 to carry out these activities.
*If enacted, this bill would authorize $6 million per year for FY2026–2030, increasing federal spending by about $30 million over that five-year period.*
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Medicare tests to delay dialysis
If enacted, HHS would run Medicare experiments to test treatments for rare kidney disease. The focus would be on options that delay or avoid dialysis or transplant. HHS would also study how to raise public awareness of rare kidney disease. A report to Congress would be due within 24 months of enactment.
New centers for rare kidney disease
If enacted, NIH could fund regional Centers of Excellence for rare kidney disease. Centers could cover patient care needed for research and provide training and outreach, including urinalysis and genetic testing. Outreach would target rural and underserved communities and include renal diet and family support resources. Each center could get support for up to 5 years, with possible 5-year extensions after review. The bill would authorize $6 million each year for 2026–2030 and require research on genes and disease, while barring QALY/DALY-style measures.
National study on kidney testing
If enacted, HHS would study testing, prevention, precision medicine, and care for rare kidney disease. The study would review urinalysis, biopsies, genetic tests like APOL1, insurance and counseling access, and treatment patterns across Medicare, Medicaid, and private plans. HHS would consult with providers, patient groups, payors, and public health and coordinate with NIH, CMS, HRSA, and CMMI. A report to Congress would be due within 18 months. The bill would authorize $1 million each year for 2026–2030.
More kidney training for doctors
If enacted, grants could fund nephrology fellowships, including stipends for postgraduate trainees. Training would focus on preventing, diagnosing, and treating rare kidney disease, including APOL1 risks, and improving care for affected communities. The bill would also add kidney disease to required topics in primary care training programs.
Sponsors & CoSponsors
Sponsor
Bilirakis
FL • R
Cosponsors
Sewell
AL • D
Sponsored 2/24/2025
Miller (WV)
WV • R
Sponsored 2/24/2025
Peters
CA • D
Sponsored 2/24/2025
Balderson
OH • R
Sponsored 2/24/2025
Tonko
NY • D
Sponsored 2/24/2025
Schneider
IL • D
Sponsored 2/24/2025
Davis (IL)
IL • D
Sponsored 2/24/2025
Lieu
CA • D
Sponsored 3/3/2025
Dunn (FL)
FL • R
Sponsored 3/10/2025
Fitzpatrick
PA • R
Sponsored 3/11/2025
Crenshaw
TX • R
Sponsored 3/14/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 5/7/2025
Suozzi
NY • D
Sponsored 5/14/2025
Brownley
CA • D
Sponsored 5/19/2025
Obernolte
CA • R
Sponsored 5/19/2025
Lawler
NY • R
Sponsored 5/19/2025
Castor (FL)
FL • D
Sponsored 6/3/2025
Davis (NC)
NC • D
Sponsored 6/6/2025
Wilson (SC)
SC • R
Sponsored 6/23/2025
Tlaib
MI • D
Sponsored 6/30/2025
Johnson (GA)
GA • D
Sponsored 7/23/2025
Ryan
NY • D
Sponsored 7/23/2025
Nadler
NY • D
Sponsored 7/25/2025
Garbarino
NY • R
Sponsored 7/25/2025
Bishop
GA • D
Sponsored 7/25/2025
Correa
CA • D
Sponsored 7/29/2025
McGovern
MA • D
Sponsored 7/29/2025
Jackson (IL)
IL • D
Sponsored 8/1/2025
Crow
CO • D
Sponsored 8/5/2025
Soto
FL • D
Sponsored 8/12/2025
Lofgren
CA • D
Sponsored 8/12/2025
Green, Al (TX)
TX • D
Sponsored 8/12/2025
Ross
NC • D
Sponsored 8/12/2025
Menendez
NJ • D
Sponsored 8/19/2025
McBride
DE • D
Sponsored 8/26/2025
Kim
CA • R
Sponsored 9/3/2025
Ocasio-Cortez
NY • D
Sponsored 9/3/2025
Vindman
VA • D
Sponsored 9/3/2025
Van Drew
NJ • R
Sponsored 9/30/2025
Ivey
MD • D
Sponsored 9/30/2025
Stevens
MI • D
Sponsored 10/21/2025
Carey
OH • R
Sponsored 10/21/2025
Flood
NE • R
Sponsored 11/4/2025
Cuellar
TX • D
Sponsored 11/4/2025
Vasquez
NM • D
Sponsored 12/17/2025
Kiggans (VA)
VA • R
Sponsored 2/26/2026
Lee (NV)
NV • D
Sponsored 2/26/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in